Coherus Biosciences | CHRS - Equity Capital And Reserves


Coherus Biosciences reported $61.01M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Fujifilm JPY 3.84T 119.25B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026
Zoetis USD 3.23B 98M Mar/2026